A phase I-II study with intraperitoneal cisplatin plus systemic etoposide in patients with minimal residual ovarian cancer
- 31 March 1992
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 28 (2-3) , 479-481
- https://doi.org/10.1016/s0959-8049(05)80081-4
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.Journal of Clinical Oncology, 1991
- Formation of interaction products of carboplatin with DNA in vitro and in cancer patientsBritish Journal of Cancer, 1991
- Pharmacokinetics of carboplatin at a dose of 750 mg m-2 divided over three consecutive daysBritish Journal of Cancer, 1990
- Intraperitoneal carboplatin in the treatment of minimal residual ovarian cancerGynecologic Oncology, 1990
- Platinum distribution inintraperitoneal tumors afterintraperitoneal cisplatin treatmentCancer Chemotherapy and Pharmacology, 1990
- Effect of Sodium Thiosulfate on the Pharmacokinetics and Toxicity of CisplatinJNCI Journal of the National Cancer Institute, 1989
- High-dose chemotherapy with autologous bone marrow transplantation in patients with refractory ovarian cancerEuropean Journal of Cancer and Clinical Oncology, 1989
- Pharmacokinetics of high dose etoposide (VP 16–213)European Journal of Cancer and Clinical Oncology, 1986
- RANDOMISED TRIAL COMPARING TWO COMBINATION CHEMOTHERAPY REGIMENS (HEXA-CAF VS CHAP-5) IN ADVANCED OVARIAN CARCINOMAThe Lancet, 1984